Popular on Rezul
- Honoring Black History, Culture, and Community in Fall River
- Token-Operated Sake Service Opens at Tobu Nikko Station
- Cheryl Hines' Trailer PROWLING to Sardinia
- Integris Composites Joins Paris Air Show at USA Pavilion
- Real Estate Buyers and Sellers Marry The Home Date The Rate
- Corner Property Management Now Managing Van Wagenen Terrace COA in Jersey City, NJ
- New Study Reveals Nearly Half Of TikTok Shop Stores Generate Zero Sales Despite Platform's $100 Million Black Friday Success
- Global Court Momentum Builds Against Forced Psychiatry; CCHR Urges U.S. Reform
- Experience Trembling Firsthand with the New AgeMan® Tremor Simulator
- Mensa Foundation Prize Awarded to Neuroscientist-Pianist
Similar on Rezul
- SacraPod Suites Unveils AI-Powered 'Work + Rest' Smart Hospitality Model for Retrofitting Underused Motels Across the U.S
- New Release: 'The Invisible Alternative' Unveiled by Atrisk Corporation, Resilient
- Real Estate Experts Highlight Jersey Shore as a Smart Buy in 2025
- $18 Price Target Issued in New Research Report After $34 Million Revenue Forecast from Acquisition; $101.5 Million Net Revenue in 2025; NAS DAQ: IQST
- The AML Shop Launches New Financial Investigations Unit, Appoints Director to Lead the Initiative
- New Podcast "Spreading the Good BUZZ" Hosted by Josh and Heidi Case Launches July 7th with Explosive Global Reach and a Mission to Transform Lives
- Drone Light Shows Emerge as the New Standard in Live Event Entertainment
- Skyline Partners with ZenSpace to Offer Private Meeting Pods for Trade Show Exhibitors
- AI Innovation Dual-Strategy Business Model Focused on Real Estate Development for Strategic Expansion: OFA Group, (N A S D A Q: OFAL)
- Valley Sleep Therapy Expands to Prescott with New Location at Crossings Road
Arcus Biosciences Announces New Employment Inducement Grants
Rezul News/10608101
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the Compensation Committee of the Company's Board of Directors granted seven new employees options to purchase a total of 11,400 shares of the Company's common stock at an exercise price per share of $27.17, which was the closing price on November 23, 2022, and restricted stock units to acquire a total of 5,700 shares of the Company's common stock. The equity awards were granted pursuant to the Company's 2020 Inducement Plan, which was approved by the Company's Board of Directors in January 2020 pursuant to the "inducement exception" under NYSE Listed Company Manual Rule 303A.08.
About Arcus Biosciences
Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination medicines for people with cancer. In partnership with industry partners, patients and physicians around the world, Arcus is expediting the development of first- or best-in-class medicines against well characterized biology and pathways and studying novel, biology-driven combinations that have the potential to help people with cancer live longer. Founded in 2015, the company has expedited the development of six investigational medicines into clinical studies, including new combination approaches that target TIGIT, PD-1, the adenosine axis (CD73 and dual A2a/A2b) and most recently, HIF-2alfa. For more information about Arcus Biosciences' clinical and pre-clinical programs, please visit www.arcusbio.com or follow us on Twitter.
More on Rezul News
Inducement PR
Source: Arcus Biosciences
Contacts
Investor and Media Inquiries:
Holli Kolkey
VP of Corporate Communications
(650) 922-1269
hkolkey@arcusbio.com
About Arcus Biosciences
Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination medicines for people with cancer. In partnership with industry partners, patients and physicians around the world, Arcus is expediting the development of first- or best-in-class medicines against well characterized biology and pathways and studying novel, biology-driven combinations that have the potential to help people with cancer live longer. Founded in 2015, the company has expedited the development of six investigational medicines into clinical studies, including new combination approaches that target TIGIT, PD-1, the adenosine axis (CD73 and dual A2a/A2b) and most recently, HIF-2alfa. For more information about Arcus Biosciences' clinical and pre-clinical programs, please visit www.arcusbio.com or follow us on Twitter.
More on Rezul News
- Cynthia Pinot Among Artists Selected for Renowned London Art Biennale 2025
- Real Estate Experts Highlight Jersey Shore as a Smart Buy in 2025
- Networking For A Cause - NYC Professionals come together to network for a cause
- "Navigating Florida's New Condo Laws: What Central Florida Owners & Buyers Need to Know"
- $18 Price Target Issued in New Research Report After $34 Million Revenue Forecast from Acquisition; $101.5 Million Net Revenue in 2025; NAS DAQ: IQST
Inducement PR
Source: Arcus Biosciences
Contacts
Investor and Media Inquiries:
Holli Kolkey
VP of Corporate Communications
(650) 922-1269
hkolkey@arcusbio.com
Filed Under: Business
0 Comments
Latest on Rezul News
- The Herbal Care, Led by Markel Bababekov, Becomes a Top Dispensary in NYC's Upper East Side
- Digital Watchdog Launches New myDW Cloud Services
- Nevada Real Estate Agent David Crane Helping Families Find Their Dream Home
- Stan Fitzgerald Appointed Acting Press Secretary for Veterans for America First VFAF Georgia State Chapter
- Drone Light Shows Emerge as the New Standard in Live Event Entertainment
- Lore Link is Here to Help Organize Your Game
- Chappaqua's Annual Townwide Summer Sale – Unbeatable Savings at Your Favorite Local Boutiques!
- Skyline Partners with ZenSpace to Offer Private Meeting Pods for Trade Show Exhibitors
- Garden City Realty recognizes top REALTOR®s of the Month and Quarter
- Maui Investment Property Realtor Shares the Wonders of Stargazing on Maui!
- Houston Office Market Report | Q2 2025
- Yes, Islamorada is The Fishing Capital of The World, Here's Why!
- Corner Property Management Selected as New Management Company for Orange COA
- AI Innovation Dual-Strategy Business Model Focused on Real Estate Development for Strategic Expansion: OFA Group, (N A S D A Q: OFAL)
- Construcción del Corredor Norte–Sur (NSC) de Singapur
- New Report: Slip and Fall Accidents Rank as the Leading Cause of Construction Site Fatalities
- Veteran Home Advantage Expands to Virginia, Offering $0 Down and $0 Closing Costs to Veterans
- Get Your Cowboy Boots On! Causeway Country BBQ Music Festival Kicks Off September 12–14 in Ft. Pierce
- Retired Hobbyist Launches Bold Weekly Album Project Using AI Songwriting Tools
- DimHum Launches Revolutionary CrowdShipping Service